Senti Biosciences

Each year, approximately 20,800 people in the U.S. are diagnosed with #AML, and many face poor outcomes within the first year. We’re working to advance next-generation approaches that aim to change that. $SNTI #Leukemia #Oncology

Our CEO, Tim Lu, highlighted a transformational milestone as positive FDA RMAT feedback advances SENTI-202 toward a potential registrational study in relapsed/refractory AML. Read more here: bit.ly/4wv4mCD $SNTI #AML #Oncology #CellTherapy

Our Chief Medical Officer, Kanya Rajangam, highlighted strong momentum for SENTI-202, supported by encouraging clinical activity, a favorable safety profile, and advancements in donor selection. Learn more: bit.ly/4wv4mCD $SNTI

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program bit.ly/4wv4mCD $SNTI

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase bit.ly/4dpqGFi $SNTI #CellTherapy #Oncology #AML

Senti Bio was founded to build a new generation of smarter medicines designed to address complex diseases using novel and unprecedented approaches. $SNTI #AML #Oncology

This #WorldDNADay, we recognize the power of genetic science in advancing new approaches to cancer treatment. At Senti Bio, we’re leveraging gene circuits to drive innovation in cell and gene therapy. $SNTI #Oncology #AML

On #AMLWorldAwarenessDay, we recognize the urgency to advance research and bring forward new therapies. Because behind every diagnosis is a life, a family, and a future. We acknowledge the importance of continuing to push science forward to create new possibilities for patients.

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 bit.ly/3QgGnqb $SNTI #CellTherapy #Oncology #AML

Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies bit.ly/4cgkRue $SNTI #CellTherapy #Oncology #AML

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update bit.ly/3PBFecv $SNTI #CellTherapy #Oncology #AML

Founded to develop a new generation of smarter medicines, Senti Biosciences is advancing innovative approaches to outsmart complex diseases and redefine what’s possible in medicine. $SNTI #Oncology #AML

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference bit.ly/4t6OzHS $SNTI #CellTherapy #Oncology #AML

Want to hear about our latest progress? Stay in the loop by signing up for our email alerts. bit.ly/3ZVnb39 $SNTI #Oncology #AML

Senti Biosciences is heading to the Leerink Global Healthcare Conference, March 8-11 in Miami Beach, FL! Join us for our presentation on March 9th from 2:20–2:50 PM as we share updates on our cell engineering platform and pipeline. Don't Miss It: bit.ly/3MIYyDL $SNTI

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026, at 2:20 PM ET bit.ly/4ubbJ1a $SNTI #CellTherapy #Oncology #AML

Senti Bio is a clinical-stage company advancing a new generation of cell and gene therapies for patients living with incurable diseases. $SNTI #Oncology #AML

Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference on Monday, March 2nd at 3:10 PM ET bit.ly/4aPOAs2 $SNTI #CellTherapy #Oncology #AML

Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development bit.ly/4rZXiLe #CellTherapy #Oncology #AML

Stay up to date on our latest news, clinical progress and company updates. Sign up for email alerts: bit.ly/3ZVnb39 $SNTI #Oncology #AML